35 results about "Kidney stone" patented technology

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

A medical device for retrieval of kidney stone fragments from a urinary tract is provided. The medical device has a plurality of magnets arranged within a flexible sheath forming a flexible wire. The magnets are magnetically attached end-to-end and arranged with their magnetic polarities alternating in direction. The magnetization direction of each of the magnets is orthogonal to the length axis of the flexible wire. A removable inner stylet is situated within the flexible sheath allowing for modifiable flexibility of the wire. The medical device is dimensioned to be introduced into the urinary tract and standard endoscopic devices. The medical device is further dimensioned to allow for the wire with magnetically attached stone fragments to be retrieved from the urinary tract. The magnetic field along the length axis is sufficient to attract to the surface of the flexible wire superparamagnetic nanoparticles which have bound themselves to kidney stone fragments.

Implementations of the present disclosure generally relate to medical aspiration devices and their methods of use. In some cases, the devices are configured to create a vacuum to capture and / or immobilize a solid deposit at a location internal to a subject. Such configurations may be useful, for example, for removing intact kidney stones small enough to pass through the ureter. In some cases, the devices further include an ablation instrument. Such devices may be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location internal to the subject (e.g., ablating kidney stones that are too large to pass through the ureter). In some cases, the vacuum created by the devices is used to remove the plurality of smaller particles from the location internal to the subject.

Implementations of the present disclosure generally relate to medical aspiration devices and their methods of use. In some cases, the devices are configured to create a vacuum to capture and / or immobilize a solid deposit at a location internal to a subject. Such configurations may be useful, for example, for removing intact kidney stones small enough to pass through the ureter. In some cases, the devices further include an ablation instrument. Such devices may be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location internal to the subject (e.g., ablating kidney stones that are too large to pass through the ureter). In some cases, the vacuum created by the devices is used to remove the plurality of smaller particles from the location internal to the subject.

Embodiments of the present disclosure generally relate to medical aspiration devices and methods of use thereof. In some cases, the devices are configured to generate a vacuum to capture and / or immobilize solid deposits at a location within a subject. Such configurations can be useful, for example, for removing intact kidney stones that are small enough to pass through a ureter. In some cases, the devices further include ablation instruments. Such devices can be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location within a subject (e.g., ablating a kidney stone that is too large to pass through a ureter). In some cases, the vacuum generated by the devices is used to remove the plurality of smaller particles from the location within the subject.

The invention discloses an application of a fibroblast growth factor 2 in preparation of a medicine for preventing and / or treating calcium oxalate kidney stone, and breaks through the technical prejudice that FGF-2 mainly promotes renal fibrosis in the prior art. It is found and proved for the first time that exogenous supplement FGF-2 can play a significant therapeutic effect in a calcium oxalate kidney stone model. Animal experiments prove that through intraperitoneal injection of FGF-2 (0.1 mg / kg / day), calcium salt crystal deposition in kidney tissue can be effectively reduced (Von Kossa dyeing verification), structural damage of renal tubular epithelial cells is relieved, inflammatory response is inhibited (HE dyeing verification), and meanwhile the serum creatinine and urea nitrogen level is remarkably improved. The invention provides a brand new molecular target and drug strategy for treatment of kidney stone, can be used as an effective auxiliary scheme of the existing physical lithotripsy technology, and reduces the risk of stone residue and recurrence.

This application discloses a biomarker for calcium oxalate kidney stones and its application, relating to the field of pharmaceutical technology. Specifically, it proposes a biomarker for calcium oxalate kidney stones, namely isolithocholic acid. It reveals that isolithocholic acid directly targets and activates the PARP1 protein, inducing parthanatos in renal tubular epithelial cells, leading to cell damage and a microenvironment conducive to crystal adhesion, ultimately driving kidney stone formation. Isolithocholic acid is specifically elevated in feces, serum, kidney, and urine in a calcium oxalate kidney stone model, and its spatial localization is associated with areas of renal tubular damage, indicating its high relevance as a diagnostic or risk warning biomarker.

This invention belongs to the field of biomedical technology, specifically disclosing the use of neuron-derived neurotrophic factors in the preparation of drugs for the prevention and treatment of kidney stones. Using a glyoxylate-induced mouse model of kidney calcium deposition, this invention demonstrates that neuron-derived neurotrophic factors can significantly reduce kidney calcium deposition, alleviate renal tubular structural damage, and improve renal function indicators. This achieves comprehensive intervention in the entire process of kidney stone disease, from crystal formation to tissue damage to functional abnormalities, exhibiting superior technical effects compared to single stone-dissolving or stone-expelling strategies, and possesses significant application value and clinical translational potential.

The invention belongs to the field of biomedicine, and relates to application of Herbacetin in prevention of renal nipple calcium spot related calcium oxalate kidney stone. The invention relates to an application of Herbacetin or pharmaceutically acceptable salt, ester, solvate, crystal form or prodrug thereof in preparation of a reagent for preventing renal papillary calcium spot related calcium oxalate kidney stone, the Herbacetin has the following structural formula: the Herbacetin is used for preventing and treating renal interstitial calcium salt deposition and Randall plaque progress for the first time, and experiments prove that the Herbacetin can be used for preventing and treating renal interstitial calcium salt deposition and Randall plaque progress. Herbacetin has the effect of inhibiting the inflammation induction of renal interstitial hydroxyapatite crystals on fibroblasts, and has the application prospect of improving the immune microenvironment of renal interstitial and the deposition of renal interstitial calcium salt.

The application provides rhamnogalacturonan I, a pharmaceutical composition and a preparation method and application thereof, and belongs to the field of biotechnology and chemistry.A new rhamnogalacturonan I is separated from polygonum aviculare, and the structure and performance of the rhamnogalacturonan I are characterized.It is found that the new rhamnogalacturonan I can play an anti-kidney stone role.The new rhamnogalacturonan I has important clinical significance and application prospect in preparation of a medicine for preventing and / or treating kidney stones.

According to the invention, a human renal cortex proximal tubule epithelial cell HK2-CaOx model and a rat kidney stone animal model are adopted, differential modified proteins are analyzed and verified through a protein modification omics technology, and key factors and key sites of lactic acid modification participating in regulation and control of kidney stone generation are identified; single cell sequencing is combined with space transcriptome analysis, identification and subdivision of kidney cell subgroups, and differential expression ligand and receptor pairs and key signal channels of macrophages and renal tubular epithelial cells are analyzed through cell communication. On the basis, the key function of the LDHB protein lactic acid modification site K156 in the kidney stone progress process is identified, and a new molecular marker and a treatment target are provided for early diagnosis of kidney stone and intervention of kidney stone.

Implementations of the present disclosure generally relate to medical aspiration devices and their methods of use. In some cases, the devices are configured to create a vacuum to capture and / or immobilize a solid deposit at a location internal to a subject. Such configurations may be useful, for example, for removing intact kidney stones small enough to pass through the ureter. In some cases, the devices further include an ablation instrument. Such devices may be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location internal to the subject (e.g., ablating kidney stones that are too large to pass through the ureter). In some cases, the vacuum created by the devices is used to remove the plurality of smaller particles from the location internal to the subject.

The invention discloses a siRNA (small interfering Ribonucleic Acid) for inhibiting the gene expression of a urate transporter 1 (URAT1) in a human body cell, and particularly discloses a siRNA (small interfering Ribonucleic Acid) for inhibiting the gene expression of the URAT1 in the human body cell. According to the invention, a plurality of siRNAs which can be used for inhibiting URAT1 expression are screened, and on the basis, proper modification is carried out to improve the silence ability of a target. The medicine taking the siRNA as the activity is expected to be clinically applied to prevention and treatment of diseases such as gout, hyperuricemia, gouty arthritis, kidney stone and the like related to URAT1 targets.

Devices for guiding an instrument into a body of a patient, at a targeted point of entry and along an insertion path at a targeted insertion angle, are described herein, such as a guide for an access needle in a PCNL procedure for accessing the kidney to remove kidney stones. The devices include base component aligned with a point of entry, and a guide assembly which cooperates with the base component to allow an instrument to be aligned and fixed at various circumferential and vertical angles. The devices and methods allow a medical professional to accurately and stably guide an instrument at a targeted point and angle and to a desired depth, while minimizing the exposure to radiation used to image the insertion path.

A laser-based system and method for treating kidney stones. The system may include a laser configured to emit pulsed laser energy and a controller configured to control the laser. The laser may be modulated to operate in one of the following modes of operation: pulverization, fragmentation, or reduced backward movement. One or more of these modes of operation may include pulses composed of subpulses.

The invention discloses application of calycosin-7-glucoside in a medicine for treating kidney stone, and the calycosin-7-glucoside can prevent / treat kidney stone, so that the calycosin-7-glucoside can be used for preparing the medicine for treating kidney stone and the medicine for preventing kidney stone formation, and a new medicine and a new treatment thought are provided for treating or preventing calcium oxalate kidney stone diseases.

The invention discloses a medicinal moxa composition for preventing and treating chronic nasosinusitis and kidney stone co-disease. The medicinal moxa composition comprises asarum, gardenia jasminoides, agilawood and moxa. The medicinal moxa composition disclosed by the invention generates an external preparation with synergistic effects of smoke, medicinal gas and heating power through combustion. Volatile components of the four medicines are burnt to form a composite pharmacodynamic system which is absorbed by skin, mucous membrane and respiratory system to generate a unique treatment effect. The medicinal moxa composition can realize cold-warm balance, multi-target coordination, immunoregulation, anti-inflammatory action and diuresis metabolism regulation through the synergistic effect of heating power and volatile matters, so that the dual effects of preventing and treating nasosinusitis and kidney stone are achieved. Due to the external use characteristic, the traditional Chinese medicine composition can directly act on body surface acupuncture points and is conducted to related viscera through meridians and collaterals to form a treatment path from the outside to the inside.

This invention relates to a system for performing medical procedures and a medical device for removing kidney stones. In one aspect, a system for performing medical procedures to remove kidney stones is provided, the system comprising: a first medical instrument configured for percutaneous insertion into a treatment site, the first medical instrument including a first fluid channel and a second fluid channel; a second medical instrument configured to be advanced through a patient lumen into the treatment site, the second medical instrument being deployed with a lithotripter; and a jet control system including a processor, wherein the processor is configured to: provide flushing to the treatment site through the first fluid channel of the first medical instrument; hold the kidney stone against the first medical instrument using at least one of the flushings provided through the first fluid channel; and break up the held kidney stone using the lithotripter deployed by the second medical instrument.

The invention belongs to the technical field of traditional Chinese medicine oral water decoction preparation, and particularly relates to a stable and safe preparation method of a traditional Chinese medicine composition water decoction for treating hepatic duct, gallbladder and kidney lithiasis, which is prepared by decocting the following traditional Chinese medicines by weight: 60g of raw lysimachia christinae hance, 60g of lygodium japonicum, 60g of white poria and 30g of endothelium corneum gigeriae galli. During decoction, the medicine is poured into a disinfected and cleaned porcelain gallipot, is soaked in a proper amount of cold water for 30 minutes, is boiled with big fire and slowly decocted with small fire for 20 minutes, is turned off, is cooled and is drunk when the temperature is low. The four traditional Chinese medicines are mixed and decocted with water according to a classical traditional technique in combination with a modern water decoction process to obtain a water decoction traditional Chinese medicine, and the water decoction traditional Chinese medicine is orally taken to prepare the traditional Chinese medicine water decoction which is remarkable in effect and convenient to take. The comprehensive regulation and enhancement formula is characterized in that lysimachia christinae hance, lygodium japonicum, white poria and endothelium corneum gigeriae galli are used as essential medicines for treating liver duct and kidney stone, removing and dissolving stone, diminishing inflammation and relieving pain. The traditional Chinese medicine composition for treating hepatic duct and kidney stone has the components of resisting bacteria, removing petrifaction, relieving depression, eliminating dampness, heat and viruses, diminishing inflammation, dissolving stone, relieving exterior syndrome, relieving pain and promoting urination to remove stasis. Through compatibility of the four traditional Chinese medicines, the traditional Chinese medicine has the remarkable effects of removing hard rock, treating leaching stone, effectively detoxifying, softening hard mass, removing stone, discharging pathogenic microorganisms of calculus, dissolving calculus caused by damp-heat effusion inflammation of hepatic duct and kidney calculus proteus, effectively enhancing the functions of each immune system, and preventing calculus from forming a radical treatment.

The present disclosure teaches multi-classification of endoscopic imaging using segmented neural networks. The network trains the imaging data using a novel loss function with components of both focus loss and boundary loss. During a lithotripsy procedure, an image is received by a deployed endoscopic probe. Based on the received imaging data and inference data from its previously learned, the segmentation neural network identifies kidney stones and surgical instruments within the imaging data. The imaging data is modified and displayed to assist in lithotripsy procedures.

A method and system for guiding renal stone removal. The method includes steps for facilitating or guiding three stages of the intervention: renal access, stone removal, and a stone-free check. This is facilitated by a method which includes three stages: an intra-operative image guidance phase for obtaining CT-based imagery of the renal area; a renal access guidance phase in which the aforementioned CT-based imagery is used to generate intervention guidance imagery to guide renal access, and a stone-free check phase in which further intra-operative CT images are acquired to check the stone-free status of the patient.

The present disclosure teaches determining kidney stone size based on calibration data generated from an endoscopic imager. During a lithotripsy procedure, an image is received by a deployed endoscopic probe. Based on the received imaging data, the generated calibration data, and known characteristics of the endoscope probe, one or more kidney stones in the image are identified and sized. And displaying the determined size value together with the kidney stone image.

The invention belongs to the field of biology, and particularly relates to clinacanthus nutans concentrated enzyme juice as well as a preparation method and application thereof. According to the clinacanthus nutans concentrated enzyme juice disclosed by the invention, clinacanthus nutans is taken as a main raw material, ingredients such as agilawood leaves, mulberry leaves, haws, morinda citrifolia, turmeric and fresh ginger are matched, meanwhile, tropical fruits such as papaya and passion fruits are added, and after step-by-step fermentation, the prepared enzyme concentrated juice has remarkable effects of resisting oxidation and reducing blood fat. The traditional Chinese medicine composition can be used for adjuvant therapy of various diseases such as nephritis, kidney stone, sore throat, hyperlipidemia and hypertension, and has remarkable health-preserving and health-care effects.

The invention discloses a traditional Chinese medicine prescription for treating lithiasis and a treatment method thereof. The invention discloses a traditional Chinese medicine prescription for treating lithiasis and a treatment method thereof, and belongs to the technical field of traditional Chinese medicines. Aiming at different pathogenesis characteristics of gall-stone and kidney stone, the prescription adopts a traditional Chinese medicine formula with dialectical compatibility to realize the treatment effect of treating both symptoms and root causes; the gallstone prescription comprises traditional Chinese medicines such as fructus gardeniae, herba lysimachiae and radix paeoniae alba, and the kidney stone prescription comprises traditional Chinese medicines such as herba pyrrosiae, fructus ligustri lucidi and lygodium japonicum; according to the treatment method, treatment based on syndrome differentiation is taken as the core, an individualized treatment scheme is formulated by determining the type, size and position of calculus and the physique of a patient, and the treatment course is adjusted by combining regular curative effect evaluation; the traditional Chinese medicine composition is scientific in prescription compatibility, exact in curative effect, simple and non-invasive in treatment method, low in cost, capable of effectively ablating calculi, promoting excretion, conditioning viscera functions and reducing the recurrence rate, solves the problems of residual tiny calculi, large trauma and the like in western medicine treatment, and is suitable for clinical treatment and popularization of lithiasis.

The utility model relates to the field of surgical instruments, and particularly discloses an endoscopic kidney stone taking-out device which comprises an inner sheath tube, an outer sheath tube and an integration part, the inner space of the inner sheath tube is a stone suction channel, and the stone suction channel is connected to an external negative pressure device and used for sucking broken stone; the outer sheath tube is sleeved outside the inner sheath tube; the space between the outer sheath tube and the inner sheath tube is a water inlet channel, and one end of the water inlet channel is located outside the body and connected with a water source; at least two channels, namely a laser channel and an endoscope channel, are arranged in the integration part in a penetrating manner, the laser channel is used for accommodating a laser optical fiber, and the endoscope channel is used for accommodating a connecting wire of an endoscope. The laser channel, the endoscope channel and other channels are integrated in a wrapping mode through the integration part, the size of the stone suction channel can be increased, and therefore the broken stone suction effect is improved; meanwhile, pressurized water injection is replaced by negative-pressure water suction, so that the pressure is convenient to control, the water pressure at the inner end of the body is reduced, and the risk of complications is reduced.

The invention relates to a composition for preventing or treating calcium oxalate kidney stone and application thereof. The invention particularly relates to a composition for preventing or treating calcium oxalate kidney stone, which comprises hydroxymalonic acid, 2, 3-diaminophenazine and a liposome carrier. The composition disclosed by the invention can be used for systematically intervening a core link of the calcium oxalate calculus and is effectively used for preventing and treating the calcium oxalate calculus.

The invention relates to an application of probiotics, and provides an application of clostridium butyricum MIYAIRI 588 viable bacteria (CBM 588) in preparation of a preparation for preventing and treating calcium oxalate kidney stone, and particularly relates to an application of the clostridium butyricum MIYAIRI 588 viable bacteria (CBM 588) in preparation of a preparation for preventing and treating calcium oxalate kidney stone. The formulation can be an orally administered formulation, and the viable bacteria can be dispersed in an aqueous carrier to form a solution or suspension. Animal model experiments show that the clostridium butyricum treatment can reduce kidney crystal or calcium salt deposition related characterization, reduce serum creatinine and urea nitrogen, regulate intestinal flora structure, improve expression of ileum tight junction protein ZO-1 and occludin, reduce serum endotoxin level and reduce the content of glycohyodeoxycholic acid in excrement, serum and kidney, and can be used for treating the kidney and the kidney. A novel preparation application is provided for preventing and treating the calcium oxalate kidney stone.

To provide a medical system, device, and method for performing laser lithotripsy on patients. [Solution] The medical device is configured to advance along the patient's urinary tract, and the system 100 further includes a console 110. The console includes one or more processors 160 and logic stored in memory 165. The logic, when executed by one or more processors, causes the system to perform the following actions: (i) project coherent light onto a kidney stone in the patient, away from the distal end; (ii) receive a reaction light signal emitted from the kidney stone in response to the coherent light; and (iii) process the reaction light signal to determine the material composition of the kidney stone. The system is also configured to project coherent light onto the kidney stone to induce fragmentation of the kidney stone, and the operation settings of the coherent light can be based on the determined composition of the kidney stone.

A steering system (1) for manipulation of a distal end of a catheter (10), including catheters used for removal of objects, such as kidney stones, is disclosed. The steering system includes an overcenter assist mechanism (32). The steering system can include a locking mechanism (50).

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.